Biomira News

A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

Wall St. Watchdog reveals information about companies for which stock analysts either upgraded or downgraded the shares on May 23rd.

The firm currently has a $4.00 price target on the stock, up from their previous price target of $2.30. Separately, analysts at Cantor Fitzgerald reiterated a "buy" rating on shares of Oncothyreon Inc .

So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks have surged in the last four months based on clinical trial results, U.S. Food and Drug Administration approval, FDA Advisory Committee's recommendation, European commission approval, recommendations from independent committees, partnership with big ... (more)

SEATTLE, WA, May 10, 2012 /PRNewswire/ - Oncothyreon Inc. announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on Wednesday, May 16, 2012 at 2:20 p.m. Pacific.

SEATTLE, May 7, 2012 /PRNewswire/ - Oncothyreon Inc. today reported financial results for the first quarter ending March 31, 2012.

SEATTLE, April 30, 2012 -- TapImmune Inc. has pleasure in announcing the appointment of Mark Reddish to the Board of Directors.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia /PRNewswire/ - Oncothyreon Inc.